|
Name |
[(1R,2S,3R,5R,8R,9S,12S,13R)-8-acetyloxy-2,2',2',9,13-pentamethyl-6,16-dimethylidene-6',11,15-trioxospiro[10,14,17-trioxapentacyclo[7.6.1.17,12.01,12.02,7]heptadecane-5,3'-pyran]-3-yl] acetate
|
Molecular Formula | C29H32O11 | |
IUPAC Name* |
[(1R,2S,3R,5R,8R,9S,12S,13R)-8-acetyloxy-2,2',2',9,13-pentamethyl-6,16-dimethylidene-6',11,15-trioxospiro[10,14,17-trioxapentacyclo[7.6.1.17,12.01,12.02,7]heptadecane-5,3'-pyran]-3-yl] acetate
|
|
SMILES |
C[C@@H]1[C@@]23C(=O)O[C@@]4([C@H](C5(O2)C(=C)[C@@]6(C[C@H]([C@@]5([C@@]3(C4=C)C(=O)O1)C)OC(=O)C)C=CC(=O)OC6(C)C)OC(=O)C)C
|
|
InChI |
InChI=1S/C29H32O11/c1-13-24(8)20(37-17(5)31)28-14(2)26(11-10-19(32)38-23(26,6)7)12-18(36-16(4)30)25(28,9)27(13)21(33)35-15(3)29(27,40-28)22(34)39-24/h10-11,15,18,20H,1-2,12H2,3-9H3/t15-,18-,20-,24+,25-,26+,27-,28?,29+/m1/s1
|
|
InChIKey |
YQYVCCPRXKJSEE-XZSIQAFASA-N
|
|
Synonyms |
Acetoxydehydroaustin B
|
|
CAS | NA | |
PubChem CID | 101534879 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 556.6 | ALogp: | 1.2 |
HBD: | 0 | HBA: | 11 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 141.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 40 | QED Weighted: | 0.282 |
Caco-2 Permeability: | -5.379 | MDCK Permeability: | 0.00005530 |
Pgp-inhibitor: | 0.984 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.51 | 20% Bioavailability (F20%): | 0.999 |
30% Bioavailability (F30%): | 0.947 |
Blood-Brain-Barrier Penetration (BBB): | 0.364 | Plasma Protein Binding (PPB): | 54.40% |
Volume Distribution (VD): | 1.456 | Fu: | 40.80% |
CYP1A2-inhibitor: | 0.006 | CYP1A2-substrate: | 0.947 |
CYP2C19-inhibitor: | 0.125 | CYP2C19-substrate: | 0.525 |
CYP2C9-inhibitor: | 0.141 | CYP2C9-substrate: | 0.004 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.024 |
CYP3A4-inhibitor: | 0.581 | CYP3A4-substrate: | 0.918 |
Clearance (CL): | 1.661 | Half-life (T1/2): | 0.109 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.966 |
Drug-inuced Liver Injury (DILI): | 0.97 | AMES Toxicity: | 0.99 |
Rat Oral Acute Toxicity: | 0.9 | Maximum Recommended Daily Dose: | 0.1 |
Skin Sensitization: | 0.369 | Carcinogencity: | 0.969 |
Eye Corrosion: | 0.73 | Eye Irritation: | 0.347 |
Respiratory Toxicity: | 0.749 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003179 | 1.000 | D03ZZK | 0.242 | ||||
ENC005316 | 1.000 | D0H2MO | 0.241 | ||||
ENC006041 | 0.880 | D0G7KJ | 0.236 | ||||
ENC005315 | 0.821 | D0KR9U | 0.233 | ||||
ENC003776 | 0.767 | D0OL7F | 0.222 | ||||
ENC004311 | 0.754 | D09SIK | 0.214 | ||||
ENC003309 | 0.741 | D08BDT | 0.213 | ||||
ENC006040 | 0.714 | D09WYX | 0.213 | ||||
ENC004811 | 0.646 | D06XHC | 0.205 | ||||
ENC004812 | 0.646 | D01ZOG | 0.201 |